SUGGESTED FORMULA

Benzoyl Alcohol 5% / Clindamycin 1% / Niacinamide 2% / Retinoic Acid 0.05% Topical Gel
Version number: 1.0
Volume or quantity: 100 mL

Benzoyl Peroxide, Hydrous, USP (BE156)	7.15 gm*
Clindamycin Phosphate, USP	1.32 gm*
Niacinamide, USP (NI105)	2gm
Retinoic Acid, USP (R1022)	0.05gm
Carbomer 941, NF (C1478)	2gm
Methylparaben, NF (ME163)	0.2 gm
Alcohol 95%, USP (ET108)	90mL
Triethanolamine	q.s.
Purified Water, USP (W1014)	10mL

7.15gm Hydrous Benzoyl Peroxide is equivalent to 5gm Benzoyl Peroxide.
1.32 gm of Clindamycin Phosphate is equivalent to 1gm of Clindamycin base.
*Adjust for water content per certificate of analysis.

Hazardous drugs should be handled according to USP and NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vertical airflow hood, in a biological safety cabinet or barrier isolation technology

SUGGESTED COMPOUNDING PROCEDURES

1. Check calculations and gather all ingredients needed for this compound
2. Measure all ingredients
3. Dissolve paraben in alcohol
4. Slowly add the Carbomer 941 with stirring to thoroughly distribute and wet the polymer
5. Slowly add the purified water. Add a few drops of Triethanolamine to attain the desired viscosity
6. Mix the Clindamycin Phosphate, Retinoic Acid and Niacinamide geometrically with the gel vehicle mixing throughly
7. Package and label and refrigerate until dispensed to the patient
8. Suggested Quality assessments:
    a. color
    b. texture
    c. container

d. Label - auxiliary labels, storage, BUD, compounded medication

*Apply very sparingly to affected area
* Keep away from eyes and mucous membranes
Store in light resistant air-tight container, refrigerated

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned based on the current USP <795> Standards

***Precautions:**
Hazardous drugs should be handled according to USP and NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vertical airflow hood, in a biological safety cabinet or barrier isolation technology. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.
8/19 JD